Analyst Viewpoint
Growth in prevalence of cancer and rise in healthcare spending are primary factors augmenting the oncolytic virus immunotherapy market value. Around 40% of men and women are likely to be diagnosed with cancer at some point in their lifetime.
Under oncolytic virus therapy, viruses are used to infect and destroy cancer cells. Increase in clinical trials in oncolytic virus immunotherapy is also boosting market progress.
Companies operating in the global oncolytic virus immunotherapy market are investing in R&D activities to launch technically advanced products.
In line with the latest oncolytic virus immunotherapy industry trends, key players are partnering with research institutes to conduct clinical trials of oncolytic viruses to introduce effective drugs for different forms of cancers.
Oncolytic virus immunotherapy entails usage of viruses in cancer treatment in order to infect and destroy cancer-affected cells. The naturally occurring virus is thus engineered to deliver therapeutic payloads to tumors and render immune-boosting molecules after tumor cells are infected.
Advantages of oncolytic virus immunotherapy include decrease in the burden of tumor via virus replication in tumorous cells.
Adenovirus-based oncolytic viruses are among the preferred viral vectors in oncolytic virus immunotherapy due to their capacity of inducing adaptive as well as innate immune responses, which are employed to deliver target antigens to hosts.
The ongoing market trend comprises several clinical trials of oncolytic viruses in conjunction with radiotherapy, chemotherapeutic agents, and immune checkpoint inhibitors that are showing positive results. For instance, T-VEC, RIGVIR, and Oncorine oncolytic viral drugs were approved for cancer treatment in 2020. They are reported to show positive therapeutic effects.
As per the American Cancer Society’s 2021 report, 1.9 million new cases of cancer were detected in 2021, with 608,570 fatalities due to cancer in the U.S. alone.
Increase in awareness regarding cancer treatments in the wake of increasing cancer-affected population and availability of advanced immune-oncology drugs are driving the oncolytic virus immunotherapy market growth.
Improper dietary habits, lack of physical activity, obesity, and rise in consumption of tobacco and alcohol are some of the factors responsible for the growth in prevalence of cancer across the globe. Genetics also plays a key role in causing cancer.
Various countries across the globe are spending increasingly on healthcare through R&D activities. The U.S. government spends significantly on healthcare every year. As per the Centers for Medicare and Medicaid Services (CMS), the U.S. healthcare spending grew to 9.7% in 2020 as compared to that in 2019.
In Europe, oncolytic virus gene therapy for lung cancer is driving the market for oncolytic virus immunotherapy as large number of lung cancer cases were detected in 2020 alone (as stated by the National Institutes of Health). It further states that healthcare expenditure related to cancer surpassed US$ 111.2 Bn in 2020.
Researchers are constantly engaged in creating new clinical trials related to oncolytic virus immunotherapy in order to find ways to improve cancer treatment and outcome. Several such clinical trials have resulted in positive results such as increase in survival rates and regression of tumor.
Rise in investments in clinical trials is one of the key factors that is fostering market development. In April 2022, Mustang Bio, Inc. announced that it would initiate a phase I clinical trial that would combine oncolytic virus and CAR T cells to treat recurrent glioblastoma (rGBM).
This initiation is a result of the interim data obtained from two investigator-sponsored Phase I clinical trials that evaluated MB-108 (C134 oncolytic virus) and MB-101 (City of Hope’s targeted CAR T therapy).
Progress in clinical trials conducted by one player is encouraging other companies to opt for such trials. This, in turn, is bolstering oncolytic virus immunotherapy market demand.
As per oncolytic virus immunotherapy market analysis, North America accounted for the largest share of the global industry in 2022. The region is projected to maintain its dominant position during the forecast period.
Growth in market statistics of North America can be ascribed to the presence of a well-developed healthcare infrastructure that is conducive to clinical trials, research collaborations between market players and academia, and positive regulatory framework that fosters innovation.
In November 2021, City of Hope, a leading cancer treatment and research center, announced inauguration of the first in-human clinical trial to evaluate usage of cancer-killing oncolytic virus for treating those affected with metastatic triple-negative breast cancer.
The therapy called CF33-hNIS-antiPDL1 is devised from chimeric oncolytic orthopoxvirus, a naturally occurring virus.
Europe also constitutes substantial oncolytic virus immunotherapy market share, with Germany and the U.K. actively participating in various research programs/clinical trials to facilitate viral oncolysis.
As per the latest oncolytic virus immunotherapy market forecast, Asia Pacific is anticipated to record steady industry growth owing to the rise in research activities pertaining to oncolytic virus immunotherapy in the region.
For instance, in June 2021, Daiichi Sankyo Company Ltd. announced that it had received a conditional approval for DELYTACT, the first oncolytic virotherapy for brain cancer in the world, from the Japan Ministry of health, Labor, and Welfare.
Companies operating in the global oncolytic virus immunotherapy landscape are engaged in collaborations and partnerships to introduce anticancer virus therapeutics through joint research.
In September 2022, Virogin Biotech announced a strategic collaboration with the University of Texas MD Anderson Cancer Center for accelerating development of various investigational treatments, including oncolytic virus immunotherapies, and identifying prognostic biomarkers of response.
Merck & Co., Inc. (Viralytics Limited), Amgen Inc., Shanghai Sunway Biotech Co., Ltd., ILT Biotherapeutics, Oncorus, Inc., Replimune Group, Inc., Oncolys Biopharma, Inc., Sorrento Therapeutics, Inc., Oncolytics Biotech, Inc., and SillaJen, Inc. are the leading players operating in the global landscape.
The oncolytic virus immunotherapy market report highlights these players in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 110.2 Mn |
| Market Forecast (Value) in 2031 | US$ 572.2 Mn |
| Growth Rate (CAGR) | 21.1% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 110.2 Mn in 2022
It is projected to advance at a CAGR of 21.1% from 2023 to 2031
Growth in incidence of cancer, rise in healthcare spending, and positive trial results
The intravenous segment accounted for the largest share in 2022
North America was the dominant region in 2022
Merck & Co., Inc. (Viralytics Limited), Amgen Inc., Shanghai Sunway Biotech Co., Ltd., ILT Biotherapeutics, Oncorus, Inc., Replimune Group, Inc., Oncolys Biopharma, Inc., Sorrento Therapeutics, Inc., Oncolytics Biotech, Inc., and SillaJen, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oncolytic Virus Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Herpes Simplex Virus
6.3.2. Vaccinia Virus
6.3.3. Adenovirus
6.3.4. Reovirus
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
7.3.1. Intratumoral
7.3.2. Intravenous
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Melanoma
8.3.2. Non-small Cell Lung Cancer (NSCLC)
8.3.3. Pancreatic Cancer
8.3.4. Breast Cancer
8.3.5. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2017-2031
10.3.1. Herpes Simplex Virus
10.3.2. Vaccinia Virus
10.3.3. Adenovirus
10.3.4. Reovirus
10.3.5. Others
10.4. Market Value Forecast, by Route of Administration, 2017-2031
10.4.1. Intratumoral
10.4.2. Intravenous
10.5. Market Value Forecast, by Application, 2017-2031
10.5.1. Melanoma
10.5.2. Non-small Cell Lung Cancer (NSCLC)
10.5.3. Pancreatic Cancer
10.5.4. Breast Cancer
10.5.5. Others
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Route of Administration
10.7.3. By Application
10.7.4. By Country
11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2017-2031
11.3.1. Herpes Simplex Virus
11.3.2. Vaccinia Virus
11.3.3. Adenovirus
11.3.4. Reovirus
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017-2031
11.4.1. Intratumoral
11.4.2. Intravenous
11.5. Market Value Forecast, by Application, 2017-2031
11.5.1. Melanoma
11.5.2. Non-small Cell Lung Cancer (NSCLC)
11.5.3. Pancreatic Cancer
11.5.4. Breast Cancer
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Route of Administration
11.7.3. By Application
11.7.4. By Country/Sub-region
12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2017-2031
12.3.1. Herpes Simplex Virus
12.3.2. Vaccinia Virus
12.3.3. Adenovirus
12.3.4. Reovirus
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Intratumoral
12.4.2. Intravenous
12.5. Market Value Forecast, by Application, 2017-2031
12.5.1. Melanoma
12.5.2. Non-small Cell Lung Cancer (NSCLC)
12.5.3. Pancreatic Cancer
12.5.4. Breast Cancer
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Route of Administration
12.7.3. By Application
12.7.4. By Country/Sub-region
13. Latin America Oncolytic Virus Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2017-2031
13.3.1. Herpes Simplex Virus
13.3.2. Vaccinia Virus
13.3.3. Adenovirus
13.3.4. Reovirus
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Intratumoral
13.4.2. Intravenous
13.5. Market Value Forecast, by Application, 2017-2031
13.5.1. Melanoma
13.5.2. Non-small Cell Lung Cancer (NSCLC)
13.5.3. Pancreatic Cancer
13.5.4. Breast Cancer
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Route of Administration
13.7.3. By Application
13.7.4. By Country/Sub-region
14. Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2017-2031
14.3.1. Herpes Simplex Virus
14.3.2. Vaccinia Virus
14.3.3. Adenovirus
14.3.4. Reovirus
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Intratumoral
14.4.2. Intravenous
14.5. Market Value Forecast, by Application, 2017-2031
14.5.1. Melanoma
14.5.2. Non-small Cell Lung Cancer (NSCLC)
14.5.3. Pancreatic Cancer
14.5.4. Breast Cancer
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Route of Administration
14.7.3. By Application
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Amgen Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc. (Viralytics Limited)
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Shanghai Sunway Biotech Co., Ltd.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. TILT Biotherapeutics
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Oncorus, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Replimune Group, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Oncolys Biopharma, Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Sorrento Therapeutics, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Oncolytics Biotech, Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. SillaJen, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 03: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 04: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 07: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 08: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 09: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 11: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 12: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 17: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 19: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 20: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 21: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
Table 23: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 24: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
List of Figures
Figure 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
Figure 02: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Type, 2022
Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2022
Figure 04: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2022
Figure 06: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Application, 2022
Figure 07: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2022
Figure 08: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2022
Figure 09: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2023-2031
Figure 10: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
Figure 11: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
Figure 12: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 13: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 14: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
Figure 15: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022-2031
Figure 16: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2022-2031
Figure 17: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2023-2031
Figure 20: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country, 2022-2031
Figure 21: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
Figure 22: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 23: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
Figure 24: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
Figure 25: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 26: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
Figure 27: Europe Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 28: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 29: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 30: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
Figure 31: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 32: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
Figure 33: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
Figure 34: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 35: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
Figure 36: Asia Pacific Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 37: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 39: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
Figure 40: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 41: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
Figure 42: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
Figure 43: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
Figure 45: Latin America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 46: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 47: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 48: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
Figure 49: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 50: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
Figure 51: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
Figure 52: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 53: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
Figure 54: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 55: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 57: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
Figure 58: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 59: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
Figure 60: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
Figure 61: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 62: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Oncolytic Virus Immunotherapy Market
